JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Analysis of cell death-related genes to evaluate the prognostic and immunotherapeutic value in bladder cancer

  • 0Department of Urology, Affiliated Tumor Hospital of Nantong University & Nantong Tumor Hospital, Nantong 226300, China.
Heliyon +

|

July 15, 2024

|

July 15, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

We identified cell demise indicators (CDIs) to predict immunotherapy effectiveness in bladder carcinoma (BLCA). CHMP4C, a key CDI, promotes BLCA progression and is linked to poor prognosis, offering insights for new therapies.

Area Of Science

  • Oncology
  • Genomics
  • Immunotherapy

Background

  • Bladder carcinoma (BLCA) treatment requires improved predictive biomarkers for immunotherapy effectiveness.
  • Cell demise indicators (CDIs) offer a novel approach to assess treatment response.

Purpose Of The Study

  • To identify prognostic cell demise indicators (CDIs) for predicting immunotherapy outcomes in BLCA.
  • To investigate the role of identified CDIs, specifically CHMP4C and GSDMB, in BLCA progression and their association with immunotherapy response.

Main Methods

  • Utilized TCGA database for differential gene expression and survival analysis to identify hub prognostic CDIs across 13 death modes.
  • Employed LASSO and Cox regression, nomogram analysis, and subtype assessment to evaluate CDI impact on prognosis and immunotherapy.
  • Investigated the regulatory network involving lncRNA XIST/NEAT1-CDIs-miR-146a-5p/miR-429 axis and performed immunohistochemical analysis for CHMP4C.

Main Results

  • Identified significant CDIs associated with BLCA prognosis and immunotherapy response.
  • Selected CHMP4C and GSDMB as key hub genes, with CHMP4C showing significant upregulation in BLCA tissues.
  • Found CHMP4C promotes BLCA progression via epithelial-mesenchymal transition (EMT) activation, correlating with unfavorable prognosis.

Conclusions

  • CHMP4C is a crucial prognostic biomarker in BLCA, negatively impacting patient outcomes.
  • The identified regulatory axis and CHMP4C's role in EMT provide potential therapeutic targets for BLCA immunotherapy.

Keywords: